The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study
Status:
Recruiting
Trial end date:
2031-06-01
Target enrollment:
Participant gender:
Summary
The REMNANT study will evaluate whether treating minimal residual disease (MRD) relapse after
first line treatment prolongs progression free survival and overall survival for myeloma
patients versus treating relapse after first line treatment at progressive disease. To
establish a homogenous group of MRD negative patients after first line treatment including
autologous stem cell transplantation, patients are enrolled at diagnosis and treated with
Norwegian standard of care first line treatment. MRD negative patients will move on to the
randomized part.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Alesund Hospital Førde Central Hospital Haukeland University Hospital Helse Nord-Trøndelag HF Helse Stavanger HF Levanger Hospital Nordlandssykehuset HF Sorlandet Hospital HF St. Olavs Hospital Sykehuset Ostfold The Hospital of Vestfold University Hospital of North Norway University Hospital, Akershus